Diekman A B, Norton E J, Klotz K L, Westbrook V A, Herr J C
University of Virginia Health Sciences Center, Center for Recombinant Gamete Contraceptive Vaccinogens, Department of Cell Biology, Charlottesville, USA.
Immunol Rev. 1999 Oct;171:203-11. doi: 10.1111/j.1600-065x.1999.tb01350.x.
A major objective in developing a sperm antigen-based contraceptive vaccine for humans is the discovery of sperm surface immunogens that are functionally relevant and sperm specific. The latter criterion is deemed essential to avoid the possibility of inducing autoimmune disease upon vaccination. This review presents evidence that a unique carbohydrate epitope is synthesized in the human epididymis, is attached to the core peptide of CD52, a lymphocyte differentiation marker, and is subsequently inserted into the sperm membrane via a glycosylphosphatidylinositol anchor. This unique CD52 glycoform is localized to the entire sperm surface, functions as a potent target for agglutinating and cytotoxic antibodies, and is one of the few well-defined sperm surface glycoproteins indicated in human antibody-mediated infertility.
开发基于精子抗原的人类避孕疫苗的一个主要目标是发现功能相关且精子特异性的精子表面免疫原。后一标准被认为至关重要，以避免接种疫苗后诱发自身免疫性疾病的可能性。本综述提供的证据表明，一种独特的碳水化合物表位在人类附睾中合成，附着于淋巴细胞分化标志物CD52的核心肽，随后通过糖基磷脂酰肌醇锚定插入精子膜。这种独特的CD52糖型定位于整个精子表面，作为凝集抗体和细胞毒性抗体的有效靶点发挥作用，并且是人类抗体介导的不孕症中少数明确的精子表面糖蛋白之一。
